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Quality of lifeAims: Atrial fibrillation (AF) and atrial flutter (AFL) are two of the most common atrial arrhythmias and
often coexist. Many patients with AF or AFL are symptomatic, which impacts their quality of life (QoL).
The purpose of this study was to determine whether coexistent AFL represents an added burden for AF
patients.
Methods: We combined baseline data from two large prospective, observational, multicenter cohort stud-
ies (BEAT-AF and Swiss-AF). All 3931 patients included in this analysis had documented AF. We obtained
information on comorbidities, medication, and lifestyle factors. All participants had a clinical examination
and a resting ECG. Symptom burden and QoL at the baseline examination were compared between
patients with and without coexistent AFL using multivariable adjusted regression models.
Results: Overall, 809 (20.6%) patients had a history of AFL. Patients with coexistent AFL more often had
history of heart failure (28% vs 23%, p = 0.01), coronary artery disease (30% vs 26%, p = 0.007), failed ther-
apy with antiarrhythmic drugs (44% vs 29%, p < 0.001), and more often underwent AF-related interven-
tions (36% vs 17%, p < 0.001). They were more often symptomatic (70% vs 66%, p = 0.04) and effort
intolerant (OR: 1.14; 95% CI: 1.01–1.28; p = 0.04). Documented AFL on the baseline ECG was associated
with more symptoms (OR: 2.30; 95% CI: 1.26–4.20; p = 0.007).
Conclusion: Our data indicates that patients with coexistent AF and AFL are more often symptomatic and
report poorer quality of life compared to patients suffering from AF only.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac
arrhythmia and is considered a public health epidemic [1,2].
Patients suffering from AF have an increased risk of stroke, heartfailure, death, and cognitive decline [3,4]. Many patients with AF
are symptomatic with untoward effects on their health-related
quality of life (QoL) [5,6]. Patients with AF have a poorer QoL com-
pared to healthy controls, the general population, or patients with
coronary heart disease [7]. Typical AF related symptoms include
palpitations, dyspnea, chest pain, effort intolerance, dizziness,
and less commonly fatigue, syncope, and anxiety [8,9].
2 S. Stempfel et al. / IJC Heart & Vasculature 29 (2020) 100556While its prevalence and incidence have been less studied than
for AF, atrial flutter (AFL) is considered as the second most com-
mon sustained atrial arrhythmia encountered in clinical practice
[10–12]. AFL tends to be associated with a rapid ventricular rate
responsible for many of its symptoms [13]. AF and AFL commonly
coexist [14], but little is known on whether this coexistence leads
to an additional symptoms- and QoL-related burden among
patients suffering from both arrhythmias. Considering that
arrhythmia-related symptoms and lower health perception are
associated with a higher risk of hospitalization [4] and are impor-
tant factors for the choice of therapeutic approach, the aim of our
study was to determine whether the coexistence of AFL was a pre-
dictor for a poorer QoL and more symptoms among patients with
AF, therefore potentially requiring a different therapy.2. Materials and methods
2.1. Study population
For this analysis, data from the BEAT-AF (Basel Atrial Fibrillation
Cohort) and Swiss-AF (Swiss Atrial Fibrillation Cohort) cohorts
were combined. Both are large prospective, observational, multi-
center cohort studies in Switzerland. Between 2010 and 2014,
the BEAT-AF Study enrolled 1553 patients with documented AF
across 7 centers in Switzerland, and 2415 patients with docu-
mented AF were enrolled in Swiss-AF between 2014 and 2017
across 13 swiss centers [15,16]. Inclusion criteria were very simi-
lar, rendering the two populations comparable. All patients had
AF that was previously documented by either 12-lead ECG, rhythm
strip, or device interrogation. Main exclusion criteria for both
BEAT-AF and Swiss-AF were the inability to sign informed consent,
the presence of exclusively short transient episodes of AF during a
reversible condition (e.g., secondary after cardiac surgery or severe
sepsis), as well as any acute illness within the last 4 weeks. For our
analysis, we excluded 37 (0.9%) patients due to missing data
regarding symptoms, quality of life or regarding a potential coexis-
tent AFL at baseline, such that 3931 patients remained in the anal-
ysis. Both study protocols were approved by the local ethics
committees, and informed written consent was obtained from each
participant.2.2. Data collection
Baseline assessment was similar for both cohorts. All study par-
ticipants were asked to complete detailed questionnaires about
lifestyle, personal, nutritional and medical factors. Smoking status
was categorized in current, past, or never smokers. We collected
information on the current medication, medical history, comor-
bidities and history of arrhythmia-related interventions (defined
as previous pulmonary vein isolation or cavotricuspid isthmus
radiofrequency ablation). The diagnosis of heart failure (HF) was
made on the basis of medical reports and only patients with a
reported diagnosis of HF, a hospitalization for heart failure or
echocardiographic signs of HF were classified as patients with a
history of heart failure. AF was classified according to current
guidelines as paroxysmal, persistent, or permanent AF [3]. During
baseline examination, patients were asked whether or not they
experienced any symptoms related with their arrhythmia. Symp-
toms potentially related to AF or AFL included palpitations, dysp-
nea, chest pain, effort intolerance, fatigue, dizziness, syncope,
anxiety or any other symptom. The precise length of the recall per-
iod was not clearly defined, but patients who had suffered symp-
toms were asked about the length and frequency of symptomatic
episodes. Patients reporting no symptoms at baseline visit were
patients with asymptomatic AF. For QoL however, patients wereasked to assess their overall health perception at the very day of
baseline examination using a visual analogue scale (VAS) ranging
from 0 (worst possible health status) to 100 (best possible health
status), similar to the extensively validated Euro-Qol VAS [5]. Addi-
tionally, in Swiss-AF more detailed information on QoL was avail-
able through the European Heart Rhythm Association (EHRA) Score
and the European Quality of life – 5 Dimensions Questionnaire
(EQ-5D). The EQ-5D-3L is a standardized instrument to assess gen-
eric health-related QoL and contains questions on five dimensions:
mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression. For each of the five dimensions, respondents are
offered three response categories (no problems, some problems,
extreme problems), leading to 243 possible health states. These
health states are then converted into index-based values (utilities)
ranging from 0 to 1 by applying a country-specific valuation algo-
rithm. As no Swiss value set is available, we used the European
Value set (VAS validated) to calculate utilities [17].
All participants also underwent clinical examination, including
measurement of body height and weight, blood pressure, and heart
rate. A resting ECG was obtained from every participant, using val-
idated devices at the local study center. We also performed a thor-
ough medical history research and collected available ECG for
every patient with reported coexistent AFL and then performed
manual ECG interpretation in order to confirm the diagnostic of
coexistent AFL.
2.3. Statistical analysis
Baseline characteristics were stratified according to the pres-
ence or absence of coexistent AFL and presented as numbers (per-
centage) for categorical variables and means ± standard deviations
for continuous variables. Among patients with coexistent AFL ver-
sus patients with AF only, data were compared using a Chi-squared
test or t-test, as appropriate.
To investigate the relationship between coexistent AFL and the
presence of symptoms, we performed logistic regression analyses
to calculate the odds ratio (OR) with corresponding 95% confidence
interval (95% CI) for the predictor coexistent AFL, using binary
symptom-related variables as the outcome (any symptom, palpita-
tions, dyspnea, fatigue, dizziness, effort intolerance, chest pain,
syncope, anxiety). The predictor coexistent AFL was additionally
classified in two groups: patients with and without cavotricuspid
isthmus (CTI) ablation, and the same regression analyses were per-
formed. Patients with CTI ablation constitute a subpopulation with
clearly proven CTI-dependent AFL while some of the remainders
may have had pseudonormalized AF or another regularized atrial
arrhythmia. Both variables were included in the same logistic
regression model. Linear regression analyses were performed to
calculate ß coefficients (95% confidence interval) for the continu-
ous outcome variables VAS (0–100) and EQ5D utilities in order to
assess the relationship between coexistent AFL (again stratified
by the presence or absence of CTI ablation) and health perception.
In a secondary analysis, we divided the study population
according to the rhythm on the ECG performed at baseline (sinus
rhythm, AF, or AFL). We excluded 82 patients due to missing ECG
and 158 others because of a different rhythm presented on the
ECG (e.g., atrial paced rhythm). The regression analyses were then
repeated for all patients using the respective heart rhythm on the
baseline ECG as the predictor and symptom-related variables and
health perception as the outcome variable. Sinus rhythm was
defined as the reference group.
All regression models were adjusted for a predefined set of
covariates. The first model was adjusted for age and sex. The sec-
ond model was additionally adjusted for body mass index, history
of hypertension, diabetes mellitus, heart failure, coronary heart
disease, and antiarrhythmic therapy. A two-sided p value < 0.05
S. Stempfel et al. / IJC Heart & Vasculature 29 (2020) 100556 3was considered to indicate statistical significance. All statistical
analyses were performed using SAS 9.4 (SAS Corporation Institute).3. Results
3.1. Baseline characteristics
We included 3931 patients with documented AF in this study.
Of these, 809 (20.6%) had known coexistent AFL. Baseline charac-
teristics stratified by the presence of coexistent AFL are presented
in Table 1. Mean age of all patients was 71 (±10) years and mean
BMI was 27.5 (±4.8). The proportion of women was significantly
lower in patients with coexistent AFL (22.7%) than in those with
AF only (29.6%). Patients with a concomitant history of AFL less
often had permanent AF (17% versus 26%, p < 0.001) and were more
likely to have a history of heart failure (28% versus 23%, p = 0.01),
coronary artery disease (30% versus 26%, p = 0.007), and renal fail-
ure (22% versus 18%, p = 0.02). Additionally, they had a higher
prevalence of unsuccessful therapy with antiarrhythmic drugs inTable 1
Baseline characteristics stratified by the presence of coexistent AFL.
All patients
(n = 3931)
Age (years) 71 ± 10
Sex (% women) 1108 (28.2)
Body mass index (kg/m2) 27.5 ± 4.8
Heart rate (beats/min) 70 ± 17
Blood Pressure (mm Hg)
– Systolic 134 ± 19
– Diastolic 78 ± 12
AF Type, %
– Paroxysmal 1928 (49.1)
– Persistent 932 (23.7)
– Permanent 1069 (27.2)
Time since diagnosis, years** 3.2 (0.8; 7.6)
– <1 year 963 (24.5)
– 1–2 years 416 (10.6)
– 2–5 years 762 (19.4)
– 5–10 years 629 (16.0)
– 10 years 625 (15.9)
Smoking Status, %
– Current 310 (7.9)
– History 1889 (48.0)
– Never 1728 (44.0)
Education, %
– Basic 477 (12.2)
– Middle 1925 (49.0)
– Advanced 1515 (38.5)
Regular physical activity, % 1899 (48.3)
CHA2DS2-VASc Score 3.2 ± 1.8
Hypertension, % 2707 (68.9)
Diabetes mellitus, % 616 (15.7)
History of Heart Failure, % 937 (23.8)
History of Myocardial Infarction, % 578 (14.7)
History of Stroke/TIA, % 672 (17.1)
History of CAD, % 1048 (26.7)
History of Renal Failure, % 733 (18.6)
Implanted device, % 690 (17.6)
History of failed AAD, % 1257 (32.0)
Antiarrhythmic drugs, %
– Class Ic 202 (5.1)
– Class II (Beta-blockers) 2707 (69.9)
– Class III 711 (18.1)
History of Intervention, %
– PVI 822 (20.9)
– CTI ablation 473 (12.0)
Data are presented as means (±standard deviation) or as counts (percentages), as appro
antiarrhythmic drugs; AF, atrial fibrillation; AFL, atrial flutter; CAD, coronary artery disea
ischemic attack. AAD were classified according to the Vaughan Williams classification.
* P-values were based on Student t tests or v2 tests, as appropriate.
** n = 536 missings.the past (44% versus 29%, p < 0.001) and more frequently under-
went a pulmonary vein isolation before enrollment (36% versus
17%, p < 0.001). Baseline characteristics of patients with coexistent
AFL stratified by their history of CTI ablation are shown in the Sup-
plementary Table 1.
3.2. Symptoms and quality of life
Prevalence of various symptom categories and health percep-
tion are shown in Table 2. Overall, two thirds of our population
presented symptoms related to atrial arrhythmias. Patients with
coexisting AFL had more often any symptoms than patients with
AF only (70% versus 66%, p = 0.04). When comparing the different
symptom categories separately, effort intolerance was more preva-
lent in patients suffering from both arrhythmias (22% versus 17%,
p = 0.003), whereas no significant differences were observed across
other symptom categories, or health perception. The prevalence of
any symptoms (75% versus 65%, p = 0.002) and palpitations (51%
versus 40%, p = 0.003) was significantly higher in AFL patients with
a history of CTI ablation compared to those without. In contrast,AF only
(n = 3122, 79.4%)
AF/AFL
(n = 809, 20.6%)
p-value*
72 ± 10 70 ± 9 0.0001
924 (29.6) 184 (22.7) 0.0001
27.4 ± 4.8 27.6 ± 4.7 0.25
70 ± 17 70 ± 18 0.83
134 ± 19 133 ± 18 0.15
78 ± 12 78 ± 12 0.95
<0.0001
1529 (49.0) 399 (49.3)
796 (25.5) 273 (33.8)
796 (25.5) 136 (16.8)
3.1 (0.8; 7.4) 3.6 (1.0; 7.8) 0.98
778 (24.9) 185 (22.9) 0.005
334 (10.7) 82 (10.1)
593 (19.0) 169 (20.9)
471 (15.1) 158 (19.5)
497 (15.9) 128 (15.8)
0.66
245 (7.9) 65 (8.0)
1486 (47.6) 403 (49.8)
1388 (44.5) 340 (42.0)
0.02
400 (12.8) 77 (9.5)
1533 (49.1) 392 (48.5)
1176 (37.7) 339 (41.9)
1458 (46.7) 441 (54.5) < 0.0001
3.2 ± 1.8 3.1 ± 1.7 0.01
2160 (69.2) 547 (67.7) 0.39
482 (15.4) 134 (16.6) 0.43
714 (22.9) 223 (27.6) 0.01
462 (14.8) 116 (14.3) 0.74
562 (18.0) 110 (13.6) 0.009
802 (25.7) 246 (30.4) 0.007
557 (17.8) 176 (21.8) 0.02
510 (16.3) 180 (22.2) <0.0001
905 (29.0) 352 (43.5) < 0.0001
151 (4.8) 51 (6.3) 0.09
2145 (68.7) 562 (69.5) 0.68
546 (17.5) 156 (19.2) 0.06
534 (17.1) 288 (35.6) < 0.0001
97 (3.1) 376 (46.5) < 0.0001
priate. Data may not sum to the given number due to missing data. AAD indicates
se; CTI, cavotricuspid isthmus ablation; PVI, pulmonary vein isolation; TIA, transient
Table 2
Symptom status and health perception according to the presence of coexistent AFL.
All patients
(n = 3931)
AF only
(n = 3122, 79.4%)
AF/AFL
(n = 809, 20.6%)
p-value* AF/AFL only p-valuey
Hx of CTI
(n = 376)
No CTI
(n = 433)
Any symptom, % 2608 (66.3) 2046 (65.5) 562 (69.5) 0.04 282 (75.0) 280 (64.8) 0.002
Palpitations, % 1661 (42.3) 1297 (41.5) 364 (45.0) 0.08 190 (50.5) 174 (40.2) 0.003
Dyspnea, % 987 (25.1) 768 (24.6) 219 (27.1) 0.16 95 (25.3) 124 (28.6) 0.28
Chest pain, % 455 (11.6) 359 (11.5) 96 (11.9) 0.77 52 (13.8) 44 (10.2) 0.11
Effort intolerance, % 712 (18.1) 536 (17.2) 176 (21.8) 0.003 91 (24.2) 85 (19.6) 0.12
Fatigue, % 702 (17.9) 549 (17.6) 153 (18.9) 0.38 81 (21.5) 72 (16.6) 0.08
Dizziness, % 598 (15.2) 463 (14.8) 135 (16.7) 0.19 67 (17.8) 68 (15.7) 0.42
Syncope, % 123 (3.1) 97 (3.1) 26 (3.2) 0.88 10 (2.7) 16 (3.7) 0.41
Anxiety, % 163 (4.1) 125 (4.0) 38 (4.7) 0.38 18 (4.8) 20 (4.6) 0.91
Health perception 71.5 71.6 71.3 0.65 72.8 69.9 0.02
VAS (mean ±SD) ±18.2 ±18.2 ±18.3 ±18.4 ±18.2
Data are shown as numbers (percentages) or as means (±standard deviation), as appropriate. The group ‘‘Hx of CTI” represents patients reporting of AFL-related cavotricuspid
isthmus ablation, whereas ‘‘No CTI” indicates no reported ablation. AF indicates atrial fibrillation; AFL, atrial flutter; VAS, Visual Analog Scale.
* P-values are based on Student t tests or v2 tests, as appropriate, and indicate differences in symptoms and health perception according to the presence or absence of
coexistent atrial flutter.
y P values are based on Student t tests or v2 tests, as appropriate, and indicate differences in symptoms and health perception within patients with coexistent atrial flutter
according to whether they underwent AFL-related cavotricuspid isthmus ablation or not.
Table 3
Relationship of coexistent AF and AFL with symptom status and health perception.
AF/AFL (all, n = 809) AF/AFL with CTI (n = 376) AF/AFL no CTI (n = 433)
Adjustment OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Any symptom Age and sex 1.07 (0.96–1.18) 0.23 1.39 (1.08–1.80) 0.01 1.04 (0.84–1.30) 0.70
Multivariate* 1.06 (0.96–1.18) 0.27 1.34 (1.04–1.74) 0.03 1.05 (0.85–1.31) 0.66
Palpitations Age and sex 1.06 (0.96–1.17) 0.26 1.31 (1.05–1.64) 0.02 1.04 (0.84–1.29) 0.72
Multivariate* 1.07 (0.97–1.19) 0.19 1.32 (1.05–1.66) 0.02 1.07 (0.86–1.33) 0.56
Dyspnea Age and sex 1.12 (1.01–1.25) 0.04 1.08 (0.84–1.39) 0.54 1.27 (1.01–1.59) 0.04
Multivariate* 1.10 (0.99–1.22) 0.09 1.02 (0.79–1.32) 0.86 1.23 (0.98–1.55) 0.07
Chest pain Age and sex 1.00 (0.86–1.16) 0.96 1.25 (0.91–1.72) 0.17 0.90 (0.65–1.26) 0.55
Multivariate* 0.99 (0.85–1.15) 0.87 1.22 (0.88–1.69) 0.22 0.90 (0.64–1.25) 0.53
Effort intolerance Age and sex 1.14 (1.02–1.29) 0.03 1.38 (1.07–1.78) 0.01 1.22 (0.94–1.58) 0.13
Multivariate* 1.14 (1.01–1.28) 0.04 1.35 (1.04–1.75) 0.03 1.22 (0.94–1.58) 0.14
Fatigue Age and sex 1.03 (0.91–1.17) 0.65 1.22 (0.93–1.59) 0.15 0.99 (0.76–1.30) 0.95
Multivariate* 1.02 (0.90–1.15) 0.81 1.18 (0.90–1.54) 0.24 0.98 (0.74–1.28) 0.86
Dizziness Age and sex 1.09 (0.95–1.24) 0.21 1.22 (0.91– 1.62) 0.18 1.14 (0.86–1.50) 0.38
Multivariate* 1.09 (0.95–1.24) 0.23 1.21 (0.90–1.61) 0.20 1.13 (0.86–1.50) 0.38
Syncope Age and sex 1.07 (0.82–1.40) 0.61 0.83 (0.43–1.61) 0.58 1.24 (0.72–2.12) 0.44
Multivariate* 1.10 (0.84–1.44) 0.48 0.88 (0.45–1.71) 0.70 1.29 (0.75–2.22) 0.36
Anxiety Age and sex 1.12 (0.89–1.41) 0.33 1.16 (0.70–1.94) 0.57 1.24 (0.76–2.02) 0.39
Multivariate* 1.14 (0.91–1.44) 0.26 1.17 (0.70–1.97) 0.54 1.29 (0.79–2.10) 0.31
b-coefficient
(95% CI)
p-value b-coefficient
(95% CI)
p-value b-coefficient
(95% CI)
p-value
Health perception
VAS 0-100
Age and sex 0.70 (1.55 to 0.16) 0.11 0.05 (1.99 to 1.89) 0.96 1.62 (3.43 to 0.19) 0.08
Multivariate 0.26 (1.09 to 0.57) 0.54 0.80 (1.10 to 2.69) 0.41 0.87 (2.63 to 0.88) 0.41
b-coefficient
(95% CI)
n = 516
p-value b-coefficient
(95% CI)
n = 232
p-value b-coefficient
(95% CI)
n = 284
p-value
EQ5D Utilities Age and sex 0.00 (0.009; 0.008) 0.87 0.005 (0.02; 0.02) 0.64 0.00 (0.02; 0.02) 0.98
Multivariate* 0.00 (0.008; 0.009) 0.95 0.005 (0.03; 0.014) 0.59 0.002 (0.015; 0.02) 0.80
ORs (95% CIs) and b-coefficient (95% CIs) are for patients with coexistent atrial flutter compared with patients with atrial fibrillation only. The group ‘‘AF/AFL with CTI”
represents AF patients with coexistent AFL reporting of an AFL-related cavotricuspid isthmus ablation, whereas ‘‘No CTI” indicates no reported ablation. AF indicates atrial
fibrillation; AFL, atrial flutter; CI, confidence interval; CTI, cavotricuspid isthmus ablation; OR, odds ratio; VAS, Visual Analog Scale.
EQ5D utilities are available in patients of the Swiss-AF study (n = 2415).
n = 3923
* Multivariable models were adjusted for age, sex, body mass index, hypertension, heart failure, diabetes mellitus, coronary heart disease (myocardial infarction, percu-
taneous transluminal coronary angioplasty, or aortocoronary bypass) and antiarrhythmic drugs.
4 S. Stempfel et al. / IJC Heart & Vasculature 29 (2020) 100556the health perception was significantly higher in these patients
(73 ± 18 versus 70 ± 18, p = 0.02).
Results of the regression models on the relationship between
coexistent AFL and symptom prevalence are presented in Table 3.
For patients with coexistent AFL, we observed a significant associ-ation with effort intolerance that persisted after multivariable
adjustment (OR: 1.14; 95% CI: 1.01–1.28; p = 0.04). In the subgroup
including AFL patients who had prior CTI ablation, associations
were significant for overall symptoms (adjusted OR: 1.34; 95%
CI: 1.04–1.74; p = 0.03), palpitations (adjusted OR: 1.32; 95% CI:
Table 4
Relationship of heart rhythm on ECG with symptom status and health perception.
AF Rhythm (n = 1610, 41.0%) AFL Rhythm (n = 80, 2.0%)
Adjustment OR (95% CI) p-value OR (95% CI) p-value
Any symptom Age and sex 0.56 (0.49–0.66) <0.0001 2.11 (1.16–3.84) 0.01
Multivariate* 0.60 (0.51–0.70) <0.0001 2.30 (1.26–4.20) 0.007
Palpitations Age and sex 0.50 (0.43–0.57) <0.0001 1.88 (1.17–3.03) 0.009
Multivariate* 0.55 (0.47–0.64) <0.0001 2.09 (1.30–3.39) 0.003
Dyspnea Age and sex 1.14 (0.97–1.33) 0.12 3.40 (2.16–5.35) <0.0001
Multivariate* 1.05 (0.90–1.25) 0.53 3.38 (2.13–5.35) <0.0001
Chest pain Age and sex 0.77 (0.62–0.96) 0.02 1.92 (1.09–3.38) 0.02
Multivariate* 0.75 (0.60–0.95) 0.02 1.95 (1.10–3.46) 0.02
Effort intolerance Age and sex 0.71 (0.59–0.85) 0.0002 1.23 (0.72–2.08) 0.45
Multivariate* 0.71 (0.59–0.85) 0.0003 1.29 (0.76–2.20) 0.36
Fatigue Age and sex 1.03 (0.86–1.24) 0.73 1.55 (0.91–2.65) 0.11
Multivariate* 1.02 (0.84–1.22) 0.86 1.60 (0.93–2.74) 0.09
Dizziness Age and sex 0.66 (0.54–0.80) <0.0001 0.73 (0.37–1.43) 0.36
Multivariate* 0.65 (0.53–0.80) <0.0001 0.72 (0.37–1.43) 0.35
Syncope Age and sex 0.41 (0.26–0.65) 0.0001 0.64 (0.16–2.66) 0.54
Multivariate* 0.43 (0.27–0.69) 0.0004 0.64 (0.15–2.67) 0.54
Anxiety Age and sex 0.46 (0.32–0.67) <0.0001 0.23 (0.03–1.65) 0.14
Multivariate* 0.50 (0.34–0.73) 0.0004 0.26 (0.04–1.91) 0.19
b-coefficient (95% CI) p-value b-coefficient (95% CI) p-value
Health perception
VAS 0-100
Age and sex 5.37 (6.57 to 4.17) <0.0001 11.66 (15.61 to 7.71) <0.0001
Multivariate* 3.69 (4.89 to 2.49) <0.0001 9.70 (13.56 to 5.84) <0.0001
ORs (95% CIs) and b –coefficient (95% CIs) are for patients in AF-, respectively AFL-rhythm, compared with patients in Sinus rhythm.
AF indicates atrial fibrillation; AFL, atrial flutter; CI, confidence interval; OR, odds ratio; VAS, Visual Analog Scale.
n = 3684.
* Multivariable models were adjusted for age, sex, body mass index, hypertension, heart failure, diabetes mellitus, coronary heart disease (myocardial infarction, percu-
taneous transluminal coronary angioplasty, or aortocoronary bypass) and antiarrhythmic drugs.
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CI: 1.04–1.75; p = 0.03). No significant associations were observed
for AFL patients without a history of CTI.
Table 4 shows the results of the secondary analysis, for which
we divided the study population according to the rhythm on the
ECG performed at baseline. Sinus rhythm was observed in 2001
patients (52.0%), AF in 1610 (41.8%) and AFL in 80 (2.1%). Symptom
status and health perception stratified by these three groups, as
well as their respective baseline characteristics, are presented in
Supplementary Tables 2 and 3. Patients who had sinus rhythm
and patients with AFL on the ECG had a significant higher symptom
burden compared to patients with AF (75% and 83% vs 57%,
p < 0.001). When comparing the individual symptoms, patients
in AFL had more palpitations, dyspnea, chest pain and effort intol-
erance, compared to patients in AF or sinus rhythm. Using patients
in sinus rhythm as the reference group, we observed a significant
association between AFL rhythm and prevalence of any symptom
(adjusted OR: 2.30; 95% CI: 1.26–4.20; p = 0.007). AFL rhythm
was also associated with palpitations (adjusted OR: 2.09; 95% CI:
1.30–3.39; p = 0.003), dyspnea (adjusted OR: 3.38; 95% CI: 2.13–
5.35; p < 0.001) and chest pain (adjusted OR: 1.95; 95% CI: 1.10–
3.46; p = 0.02). On the other hand, AF was inversely associated with
presence of any symptoms (adjusted OR: 0.60; 95% CI: 0.51–0.70;
p < 0.001), as well as for most individual symptom categories.
AFL rhythm (b-coefficient 9.70, 95% CI: 13.56 to 5.84;
p < 0.001) and AF rhythm (b-coefficient 3.69, 95% CI: 4.89 to
2.49; p < 0.001) were both associated with a lower health
perception.4. Discussion
The main results of our study are as follows: 1) One fifth of the
patients in our AF cohorts also suffered from coexistent AFL, 2)
Patients with AF and coexistent AFL are more often symptomatic
than patients with AF only, 3) Coexistent AFL is associated with
more effort intolerance and 4) Patients with AFL on their baselineECG reported a lower quality of life than AF patients in sinus
rhythm.4.1. Prevalence of coexistent AFL in AF patients
The coexistence of AF and AFL is common in clinical practice
[14]. Recent studies have suggested that the prevalence of coexis-
tent AF among AFL patients ranged between 24% and 62% [18,19].
Both arrhythmias may be different manifestations of the same
electrical heart disease [20] and some hypothesize that without
preceding AF resulting in rate dependent intraatrial block, AFL
could not develop [21]. Of our 3931 patients with documented
AF, 809 (20.6%) reported concurrent AFL. We could confirm the
diagnostic of AFL through manual ECG interpretation and medical
history research in the vast majority of patients with reported AFL
and therefore concluded that our reported prevalence of 20.6% was
not an overestimate of the true prevalence of coexistent AFL in our
cohort. It may even be an underestimate considering that AFL has
not been systematically documented in our cohorts and was eli-
cited by medical history, and that patients who did not reported
AFL and did not present with AFL rhythm on the ECG performed
at baseline were classified as patients with AF only. To our knowl-
edge we are the first to report the prevalence of AFL in a large
population-based cohort of AF patients.4.2. Symptoms and quality of life in patients with AF only and
coexistent AFL
Earlier studies indicated that patients with both AF and AFL had
less improvement in their QoL and frequency of symptoms follow-
ing AFL ablation than patients with AFL only [22,23], generating
the hypothesis that coexistence of both arrhythmias could have a
greater impact on symptom status and QoL. However, the evidence
on the impact of coexistent AF and AFL on the patients’ wellbeing is
sparse. When assessing symptom status in our population, we
found an overall prevalence of symptoms of 66.3%, confirming
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When we compared patients with coexistent AF and AFL to
patients with AF only, a higher symptom burden was found for
patients with coexistence of both arrhythmias. This difference
was observed even though the proportion of women, who are
known to have substantially more symptoms than men when suf-
fering from AF [8], was significantly higher in patients with AF only
(as shown in Table 1).
The higher symptom burden for patients with coexistent AFL
was particularly evident when our AF population was stratified
according to the rhythm present on the ECG performed during
the baseline visit. AFL rhythm emerged as a strong predictor for
overall symptoms, more palpitations, more dyspnea and more
chest pain, a finding that remained statistically significant after
multivariable adjustment. Our results also showed that coexis-
tence of AF and AFL was an independent predictor for more effort
intolerance in our population. A possible explanation for this asso-
ciation between coexistence of AFL and effort intolerance might be
that patients suffering from AFL more often received antiarrhyth-
mic drugs (see Table 1), considering AFL does typically not respond
well to antiarrhythmic drugs, treatment which predisposes them
to develop adverse effects, including effort intolerance. Patients
with coexistent AFL also reported more often a history of heart fail-
ure. This may in part be explained by poorer ventricular rate con-
trol among these patients, causing myocardial and
electromechanical remodeling, potentially resulting in tachycar-
diomyopathy [13]. Patients in AFL rhythm at baseline had a signif-
icantly higher heart rate than both patients in AF or sinus rhythm,
as well as a more frequent use of antiarrhythmic drugs (as shown
on Supplementary Table 3), which could indicate poorer rate con-
trol. When comparing patients according to the rhythm on the ECG
performed at baseline, we found that patients presenting in AFL
had a significantly higher symptom burden and poorer QoL com-
pared to patients who were either in sinus rhythm or in AF.
4.3. Differences between patients with and without cavotricuspid
isthmus ablation
Cavotricuspid isthmus (CTI) ablation is the treatment of choice
for recurrent and symptomatic AFL, with a high procedural success
rate [24] and significant QoL improvement [25]. However, coexis-
tent AF is frequently unmasked after CTI ablation for AFL [14,26].
In a meta-analysis, Pérez et al. report an overall incidence of AF
after AFL ablation of 33.6%, increasing up to 56.6% after a 3-year
follow-up [24]. Several studies now even suggest that a prophylac-
tic pulmonary vein isolation in AF should be performed in conjunc-
tion with AFL ablation, in order to improve long-term freedom
from atrial arrhythmias [27,28]. Furthermore, it has been demon-
strated that stand-alone pulmonary vein isolation prevents recur-
rence of AFL, even without CTI ablation [29]. Considering the
strong impact of CTI ablation on the arrhythmia recurrence and
that symptoms are usually linked to the arrhythmia burden [30],
as well as the fact that an improvement in quality of life could
be demonstrated for patients after CTI ablation [25], we subdivided
the group of patients with coexistent AF and AFL in those with and
without a history of CTI ablation. We observed that patients who
underwent CTI ablation had significantly more symptoms, and par-
ticularly more palpitations, than patients without CTI ablation and
patients with AF only. This seemingly surprising result is probably
due to the fact that symptoms were assessed for the period (possi-
bly before the CTI ablation had been performed) preceding the
baseline visit and therefore might not reflect the symptom status
on that very day. Furthermore, it is likely that a higher symptom
burden was the reason to undergo CTI ablation. Since we did not
follow this subgroup, we are not able to confirm that patients
who underwent CTI ablation experience a decrease of symptomburden and improvement in quality of life over the years following
the ablation, as suggested by previous studies [22,25]. Finally, it is
conceivable that patients with renewed AFL after CTI ablation suf-
fer from CTI-independent AFL which may be more symptomatic.
4.4. Differences in quality of life in relation to the baseline ECG rhythm
Quality of life perception depends on the rhythm at the time of
the baseline visit. AF strongly impacts on QoL and Steg et al.
demonstrated that among AF patients, those in sinus rhythm had
less QoL impairment than those in AF rhythm [5]. This is in line
with our findings, showing that patients in AF had an observed dif-
ference of 6 points in the VAS (see Supplementary Table 2), when
compared with AF patients in sinus rhythm. However, we observed
that AF rhythm was associated with a lower symptom burden. We
explain this result by the fact that a majority (83%) of patients pre-
senting AF on the baseline ECG had persistent or permanent type
AF, both AF types known to generate less symptoms than paroxys-
mal AF [8]. Additionally, we found that AF patients who presented
AFL on the ECG had a significantly poorer QoL than both patients in
sinus rhythm and in AF, further underscoring the additional impact
of coexistent AFL among our AF population.
4.5. Strengths and limitations
A major strength of this study is the availability of two large,
well-characterized populations of unselected AF patients. Given
the thorough assessment of a large number of study variables for
each study participant and the little exclusion rate due to missing
data, the findings of this study are of relevance.
However, several limitations need to be taken into account.
First, the cross-sectional observational study design does not allow
us to draw causal conclusions and residual confounders may be
present despite multivariable adjustment. Nevertheless, our study
suggests that differences in symptoms and QoL are not explained
by the covariates added in the models. Second, we had a low preva-
lence of patients presenting with AFL rhythm on the baseline ECG,
therefore the results obtained for this subgroup should be inter-
preted cautiously. Third, the success rates of the CTI ablations for
the different centers were not available in our data. However, pre-
vious publications showed that CTI ablation was successful in over
90% of the procedures [24] and we therefore assumed that the vast
majority of procedures succeeded. Finally, echocardiographic data
was only available for a small proportion of patients and not sys-
tematically documented, therefore differences in type of underly-
ing heart disease and severity of systolic dysfunction may impact
the patients’ QoL despite adjustment for heart failure and coronary
artery disease.
5. Conclusion
Our data from two large prospective observational cohort stud-
ies of patients with AF showed that one fifth of the patients suffer
from coexistent episodes of AFL which is associated with a signif-
icantly higher symptom burden and poorer quality of life. Further-
more, the presence of AFL on the baseline ECG was associated with
lower quality of life and more symptoms. Our data therefore sug-
gest that coexistent AFL represents an added burden for patients
suffering from AF and further studies are needed to assess the best
therapeutic approach for this specific population of patients.
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